OMedLive

Presentations

Cancer Immunotherapies


Presentations


Speakers

  • Sigrun Hallmeyer, MD

    Sigrun Hallmeyer, MD

    Sigrun Hallmeyer, MD

    Sigrun Hallmeyer, MD, is director of the Cancer Institute, medical director of the Cancer Survivorship Program, and co-director of the PRC Russell Institute for Research and Innovation at Advocate Lutheran General Hospital in Park Ridge, Illinois. Dr Hallmeyer’s clinical interests include caring for patients with breast cancer and melanoma, as well as immuno-oncology, solid cancer oncology and cancer survivorship. She earned her medical degree at Humboldt University of Berlin, completed her internal medicine residency at Pinnacle Health Hospitals in Harrisburg, Pennsylvania, and completed her fellowship in hematology and oncology at the University of Illinois at Chicago.
  • Jennifer Wang, LCSW

    Jennifer Wang, LCSW

    Jennifer Wang, LCSW

    Jennifer Wang, LCSW, is a clinical social worker in the Department of Oncology at Advocate Lutheran General Hospital in Park Ridge, Illinois. Ms Wang works with patients and families at the Cancer Survivorship Center, where she meets with patients for individual and family counseling, and facilitates support groups as well as linking patients with community resources. She has a background in private practice, counseling patients with a relational framework.
  • Mary Hurd, RN, BSN, MHA

    Mary Hurd, RN, BSN, MHA

    Mary Hurd, RN, BSN, MHA

    Mary Hurd, RN, BSN, MHA, is the manager of the Bone Marrow Transplant and Cancer Survivorship Programs at Advocate Lutheran General Hospital in Park Ridge, Illinois. Having more than 30 years of experience in working with cancer patients, Ms Hurd is devoted to improving survival and quality of life for cancer patients through standard-setting, prevention, research, education, monitoring of comprehensive quality care, and listening to the specific needs and wants of the cancer survivors themselves. Her achievements as a dedicated leader include contributions to several articles, interviews, consumer publications and poster presentations regarding survivorship needs. The Bone Marrow Transplant Program has been successfully accredited 5 times and is currently awaiting its 6th accreditation.
  • Agnes Richardson

    Agnes Richardson

    Agnes Richardson

    Agnes Richardson is a wife, mother of two, an English teacher in Crystal Lake, Illinois, and an Advocate Lutheran General Hospital patient. She is a survivor of Stage IV melanoma.
  • Jarushka Naidoo, M.B.B.Ch.

    Jarushka Naidoo, M.B.B.Ch.

    Jarushka Naidoo, M.B.B.Ch.

    Jarushka Naidoo, MBBCh, is an assistant professor of oncology at the Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Center for Cancer Immunotherapy at Johns Hopkins University in Baltimore, Maryland. She earned her medical degree from Trinity College Dublin and completed her medical oncology training in Ireland, followed by an advanced medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York. Dr Naidoo currently leads investigator-initiated trials for patients with stage III non-small lung cancer and those with CNS metastases. She is the chair of the Immunotherapy Subcommittee of the NRG Clinical Trials Cooperative Group, co-chair of the Johns Hopkins Immune-Related Toxicity Team, and serves on the NCCN Immune-Related Toxicity Panel.
  • Jennifer Mammen, MD, PhD

    Jennifer Mammen, MD, PhD

    Jennifer Mammen, MD, PhD

    Jennifer Mammen, MD, MPhil, PhD, is an assistant professor of medicine in the Division of Endocrinology at Johns Hopkins University Medical Center in Baltimore, Maryland. She earned her medical degree and PhD under a Medical Scientist Training Program award at Johns Hopkins University School of Medicine, followed by a residency and a fellowship in endocrinology, also at Johns Hopkins. Board-certified in internal medicine and endocrinology/metabolism, Dr Mammen practices general endocrinology with a focus on thyroid, adrenal and pituitary disorders. She is an NIH-funded researcher with a focus on thyroid autoimmunity and aging, and is actively engaged in research into the mechanisms of autoimmune endocrine disorders.
  • Laura Cappelli, MD, MHS

    Laura Cappelli, MD, MHS

    Laura Cappelli, MD, MHS

    Laura C. Cappelli, MD, MHS, MS, is assistant professor of medicine at the Johns Hopkins University School of Medicine, Division of Rheumatology, in Baltimore, Maryland, and a faculty member of the Johns Hopkins Arthritis Center. She earned her MD from Johns Hopkins University School of Medicine, completed her internal medicine residency and rheumatology fellowship at the Johns Hopkins Hospital, and earned her MHS in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. Dr Cappelli started a clinical/research program to evaluate the rheumatologic adverse effects of cancer immunotherapy, including clinical characteristics, epidemiology, impact on patients and biologic mechanisms. She also serves as co-chair of the Immune-Related Toxicity Team at Johns Hopkins.
  • Dan Raz, MD, MAS

    Dan Raz, MD, MAS

    Dan Raz, MD, MAS

    Dan Raz, MD, MAS, is a thoracic surgeon and co-director of the lung cancer and thoracic oncology program at City of Hope in Duarte, California. Dr Raz’s research focuses on developing therapies targeting specific epigenetic modifications in order to improve sensitivity to chemotherapy in lung cancer. He has authored dozens of articles, including studies demonstrating survival benefit for patients who choose lung cancer surgery. Dr Raz joined City of Hope in 2012 after completing fellowships at Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center and the Mayo Clinic. He earned his medical degree at the University of Pennsylvania, and a master’s degree in clinical research and biostatistics from the University of California, San Francisco.
  • Jennie R. Crews, MD, MMM, FACP

    Jennie R. Crews, MD, MMM, FACP

    Jennie R. Crews, MD, MMM, FACP

    Jennie R. Crews, MD, MMM, FACP, is medical director, Seattle Cancer Care Alliance Network and Research Integration, and an associate professor of medicine at the University of Washington. Dr Crews has over 18 years of experience in oncology in academic, private practice, and hospital-based settings. She is a fellow in the American College of Physicians, and is board-certified in internal medicine and medical oncology. She is on the editorial committee for the ACCC Drug Reference Guide, a reviewer for the Journal of Oncology Practice, and a member of the ASCO Practice Guidelines Implementation Network. She earned her medical degree from Duke University in Durham, North Carolina, where she also completed training in internal medicine and oncology, and served as assistant chief resident.
  • Jeffrey P. Gregg, MD

    Jeffrey P. Gregg, MD

    Jeffrey P. Gregg, MD

    Jeffrey Gregg, MD, is senior director of clinical pathology and molecular diagnostics, and professor of pathology at the University of California Davis School of Medicine and UC Davis Health. He is the director of the UC Davis Comprehensive Cancer Center Genomics Shared Resource, where he uses next-generation sequencing and genomic technologies for the analysis of tumors and biomarker discovery. Dr Gregg’s clinical and research focus is on developing liquid biopsy as a high-value clinical tool for cancer screening, diagnosis and surveillance. He is a member of the UC Davis Molecular Tumor Board and participates in other molecular tumor boards throughout the United States. Dr Gregg received his medical degree from the University of California, Los Angeles.